Pfizer Revenues up 77% in the Quarter

Pfizer
1Q Revenues: $25.7 billion (+77%) 
1Q Earnings: $7.9 billion (+61%) 
Comments: Vaccines sales were $14.9 billion in the quarter, up from $4.9 billion in 1Q21. Comirnaty revenues were approximately $32 billion. This guidance includes doses expected to be delivered in fiscal 2022 under contracts signed as of mid-April 2022. Paxlovid revenues were approximately $22 billion. This includes treatment courses expected to be delivered in fiscal 2022, primarily relating to supply contracts signed or committed as of mid-April 2022. Excluding contributions from comirnaty and Paxlovid, revenues increased 2% operationally. 
 
Hospital sales were $3.2 billion, up 69%. Oncology sales were $3.0 billion, up 4%. Internal Medicine sales were down 6% to $2.4 billion. Rare Disease sales were up 17% to $963 million.  Inflammation & Immunology sales were down 23% to $821 million. Pfizer CentreOne revenues were down 13% to $338 million. 
 
Prevnar family sales in the U.S. were up 59%, driven by strong retail and wholesaler stocking of Prevnar 20 for the adult indication and favorable timing of government purchases of Prevnar 13 for the pediatric indication. Global Eliquis sales were up 12% operationally. Vyndaqel/Vyndamax globally, up 41% operationally. Oncology biosimilars grew 35% operationally to $464 million, primarily driven by strong U.S. growth of Zirabev, Ruxience and Retacrit; and Ibrance outside the U.S., up 12% operationally. Ibrance in the U.S. was down 5%, due primarily to an increase in the proportion of patients accessing Ibrance through Pfizer’s Patient Assistance Program.
 
Global Chantix sales were down 99% operationally, which continues to be negatively impacted by a global pause in shipments of Chantix due to the presence of N-nitroso-varenicline above an acceptable level of intake set by various global regulators. Global Xeljanz sales were down 29% operationally, driven primarily by decreased prescription volumes globally resulting from ongoing shifts in prescribing patterns related to Janus kinase (JAK) class label changes.